27 hasil untuk "C. Conticello"
Menampilkan 1–20 · 0,69 detik · RSS
-
Artikel Jurnal
P161 | EVALUATION OF ATTRITION RATES IN REAL-LIFE SETTING: A SINGLE-CENTER SURVEY IN THE LAST 12 YEARS (2012-2024)
For multiple myeloma (MM), the proportions of patients reaching the subsequent line of therapy (LOT) decline gradually and real-world data describing the attrition rates of LOT in real-life in Italy are limited. To this end, we retrospectively evaluated 707 newly diagnosed MM, with 421 (59.5%)…
-
Artikel Jurnal
P160 | PROGRESSION FROM MGUS THROUGH SMOLDERING MYELOMA IS ASSOCIATED WITH ACQUISITION OF IMMUNE-SENESCENCE PHENOTYPE IN PERIPHERAL BLOOD
The role of B cells, in contrast to T cells, in MGUS progression is poor investigated. Recently, the expansion of CD71+ neutrophils has been defined as hallmark of ageing. We prospectively enrolled 133 adult patients (median age 66 years old, range 48-83) affected by plasma cell dyscrasias as…
-
Artikel Jurnal
Oral Lesion as Unusual First Manifestation of Multiple Myeloma: Case Reports and Review of the Literature
Extramedullary plasmacytoma (EMP) and solitary bone plasmacytoma (SBP) represent a disease continuum through a multistage process of cell differentiation, survival, proliferation, and dissemination, strictly related to multiple myeloma (MM), the second most common hematological malignancy. Herein…
-
Artikel Jurnal
Abnormal F-18 Fluorodeoxyglucose Uptake of the Lung in Immunocompromised Lymphoma Patients in Complete Remission: Report of Two Cases and Revision of Literature
Limited data suggest that F-18 fluorodeoxyglucose (FDG) positron emission tomography (PET) may have a role in diagnosing infection. Here we present two cases of lymphoma patients in complete response (CR) who presented during follow-up dry cough and fever. Physical examination and serum evaluations…
-
Artikel Jurnal
P51 | EVOLVING ATTRITION RATES IN MULTIPLE MYELOMA REAL-WORLD PRACTICE OVER A 30-YEARS PERIOD FROM A SINGLE CENTER EXPERIENCE
Therapeutic innovation in multiple myeloma (MM), through the sequential integration of immunomodulatory drugs, proteasome inhibitors, monoclonal antibodies, cellular therapies, and bispecific antibodies, has significantly improved survival outcomes. Alongside novel agents and combinations…
-
Artikel Jurnal
P57 | MELFLUFEN IS EFFECTIVE AND SAFE IN MULTIPLE MYELOMA PATIENTS WITH SEVERE RENAL IMPAIRMENT
Multiple myeloma (MM) is often complicated with renal insufficiency (RI) which adversely influences the prognosis. The incidence of RI in MM patients ranges from 20% to 50% and is primarily due to light chains deposition in the kidney. Melphalan flufenamide (melflufen) is an anti-myeloma drug…
-
Artikel Jurnal
P54 | EVOLVING OUTCOMES IN MULTIPLE MYELOMA REAL-WORLD PRACTICE: 30-YEARS SINGLE CENTER EXPERIENCE
In the last two decades therapeutic armamentarium for treatment of multiple myeloma (MM) is increased both with the introduction of novel drugs and combinations and by introducing consolidation and maintenance therapy. Life expectancy and outcomes of MM patients has remarkably improved…
-
Artikel Jurnal
P174 | EFFICACY AND SAFETY OF ISATUXIMAB, CARFILZOMIB AND DEXAME-THASONE (ISAKD) IN MULTIPLE MYELOMA PATIENTS AT FIRST RELAPSE AFTER AUTOLOGOUS STEM CELL TRANSPLANTATION AND LENALIDOMIDE MAINTENANCE: RESULTS FROM THE MULTICENTER, REAL-LIFE AENEID STUDY
In the randomized, phase-3 IKEMA trial, the triplet isatuximab, carfilzomib, and dexamethasone (IsaKd) demonstrated superior clinical benefit compared to those of carfilzomib and dexamethasone alone in patients with relapsed/refractory multiple myeloma after 1–3 prior treatments. Our real-world…
-
Artikel Jurnal
C078 | COMPARISON BETWEEN BTKIS, DRC, BR AND OTHER CHEMO-IMMUNOTHERAPEUTIC SCHEMES IN TERMS OF INFECTIONS AND NEED OF HOSPITALIZATION IN WALDENSTRÖM MACROGLOBULINEMIA
Infections are a major source of morbidity and mortality in patients (pts) with Waldenström Macroglobulinaemia (WM). Treatments with Bruton’s Tyrosine Kinase inhibitors (BTKis) have increased, with a reduction on infection rate but data on infection incidence are generally extrapolated from…
-
Artikel Jurnal
P166 | REAL-WORLD CLINICAL PRACTICE IN ITALIAN PATIENTS WITH MULTIPLE MYELOMA: PRELIMINARY ANALYSIS OF THE MY MYELOMA MULTICENTER REGISTRY
Background. The Italian, non-interventional, multicenter registry MY MYELOMA aims to monitor real-world clinical practice for multiple myeloma (MM) patients (pts). We report the preliminary analysis of the first 1049 registered pts. Methods. Pts diagnosed with symptomatic MM since 1/1/2019 were…
-
Artikel Jurnal
P178 | ARGININE DEPRIVATION INDUCES CANCER DORMANCY AND GENOMIC INSTABILITY: THE SEED AND SOIL OF MULTIPLE MYELOMA RECURRENCE
We combined multi-omics approaches to investigate the adaptive response to acute and chronic arginine deprivation, in two human myeloma cell lines (U266 and NCI-H929). We failed to identify a common trigger for the activation of integrated stress response, due to a variable expression of BIP, PERK…
-
Artikel Jurnal
DP120 | A NATIONWIDE ITALIAN SURVEY ON TANDEM AUTOLOGOUS STEM-CELL TRANSPLANTATION FOR NEWLY DIAGNOSED MULTIPLE MYELOMA TREATED WITH DARATUMUMAB-BORTEZOMIB-THALIDOMIDE-DEXAMETHASONE INDUCTION
Quadruplet induction with D-VTd followed by single ASCT is the current standard treatment for NDMM in European Countries. However, in the latest EHA guidelines tandem ASCT is still recommended as an option for high-risk (HR) patients (pts), based on previous studies suggesting a survival benefit in…